Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508613 | 0.84 | TDP1 (0.38) | GRM2SLC9A1RECQLCYP19A1LMNA | |
| SCHEMBL20535098 | 0.84 | ALDH1A1 (0.48) | LMNACYP11B1ALDH1A1KDM4E | |
| SCHEMBL3321570 | 0.82 | GRM2 (0.49) | GRM2CYP19A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL4261667 | 0.80 | HTT (0.42) | RECQLLMNAALDH1A1KDM4EGAA | |
| SCHEMBL570746 | 0.77 | SLC9A1 (0.44) | GRM2SLC9A1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20535135 | 0.76 | ALDH1A1 (0.41) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL1047732 | 0.76 | GRM2 (0.47) | GRM2LMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL29136175 | 0.76 | SLC9A1 (0.58) | SLC9A1LMNASMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL29199475 | 0.74 | SLC9A1 (0.47) | GRM2SLC9A1CNR1CNR2LMNA | |
| SCHEMBL570412 | 0.74 | TDO2 (0.39) | ALDH1A1KDM4ETSHRHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968217-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2021-04-06 | — | — | US | claimed |
| EP-3535262-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | claimed |
| US-20200062747-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | claimed |
| EP-3535262-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2019-09-11 | — | — | EP | claimed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | claimed |
| CN-102066316-A | Novel compounds derived from taurine, process for their preparation and pharmaceutical compositions containing them | EMS SA | 2011-05-18 | — | — | CN | claimed |
| CN-101827849-A | Novel compounds of reverse turn mimetics and the use thereof (1) | CHOONGWAE PHARMA CORP | 2010-09-08 | — | — | CN | claimed |
| EP-2212329-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | claimed |
| WO-2009051399-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | claimed |
| WO-1999035132-A1 | HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | claimed |
| EP-0510748-B1 | Use of a methoxy alkanoic acid of indazole for the manufacture of a medicament for the treatment of autoimmune diseases | ANGELINI RICERCHE SPA (IT) | 1996-03-20 | — | — | EP | claimed |
| EP-0382276-B1 | Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids | ACRAF (IT) | 1995-08-30 | — | — | EP | claimed |
| US-5278183-A | Benzylindazole carboxylates | INSTITUTO RICERCA FRANCESCO ANGELINI S.P.A. (IT) | 1994-01-11 | — | — | US | claimed |
| EP-0510748-A1 | Use of a methoxy alkanoic acid of indazole for the manufacture of a medicament for the treatment of autoimmune diseases | ANGELINI RICERCHE S.p.A. SOCIETA' CONSORTILE (IT) | 1992-10-28 | — | — | EP | claimed |
| US-5112986-A | Chemical intermediates for analgesics | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1992-05-12 | — | — | US | claimed |
| US-4999367-A | Analgesics | AZIENDE CHIMICHE RUINITE ANGELINI FRANCESCO A. C. R. A. F. S. P. A. (IT) | 1991-03-12 | — | — | US | claimed |
| EP-0382276-A2 | Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1990-08-16 | — | — | EP | claimed |
| JP-6040915-A | — | — | None | — | — | JP | disclosed |
| US-4999367-A | Analgesics | AZIENDE CHIMICHE RUINITE ANGELINI FRANCESCO A. C. R. A. F. S. P. A. (IT) | 1991-03-12 | — | — | US | disclosed |
| EP-0382276-A2 | Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968217-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | TPMT, DPYD, HAVCR2 | GRM2 3007/4885SLC9A1 3182/4885RECQL 82/4885 |
| US-20200062747-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TPMT, DPYD, HAVCR2 | GRM2 3165/4885SLC9A1 3517/4885RECQL 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.